Literature DB >> 7575843

Outcome of children with opsoclonus-myoclonus regardless of etiology.

M S Hammer1, M B Larsen, C V Stack.   

Abstract

Within the past 11 years, 11 patients with opsoclonus and myoclonus, with or without a history of neuroblastoma, have been admitted to Children's Memorial Hospital. Eight of the 11 children had an occult neuroblastoma. Eight children have had subsequent delayed development with motor incoordination and speech delay (7 with neuroblastoma, 1 without). Nine of 11 children initially were treated with ACTH, 1 child was treated with prednisone, and 1 was not treated. Nine of the 10 children who were treated had recurrences of symptoms during the gradual withdrawal or discontinuation of ACTH. Often the ACTH had to be restarted or increased, although several times the episodes were self-limited, not requiring treatment after ACTH was withdrawn. We found prednisone was ineffective in controlling opsoclonus-myoclonus regardless of etiology. The majority of children with opsoclonus-myoclonus, regardless of etiology, have developmental delay, more severe and at a higher rate than previously reported. When a neuroblastoma was present, tumor removal did not improve symptoms. Although limited in size, our study indicates patients with opsoclonus-myoclonus without an associated neuroblastoma have a better chance for normal neurologic development (2/3 versus 1/8).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575843     DOI: 10.1016/0887-8994(95)00083-r

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  4 in total

1.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

Authors:  F Keime-Guibert; F Graus; A Fleury; R René; J Honnorat; P Broet; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

2.  Long-term outcome of ten children with opsoclonus-myoclonus syndrome.

Authors:  Andrea Klein; Bernhard Schmitt; Eugen Boltshauser
Journal:  Eur J Pediatr       Date:  2006-11-07       Impact factor: 3.183

3.  Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.

Authors:  Nuria Gresa-Arribas; Maarten J Titulaer; Abiguei Torrents; Esther Aguilar; Lindsey McCracken; Frank Leypoldt; Amy J Gleichman; Rita Balice-Gordon; Myrna R Rosenfeld; David Lynch; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-12-18       Impact factor: 44.182

Review 4.  Update on opsoclonus-myoclonus syndrome in adults.

Authors:  Sun-Young Oh; Ji-Soo Kim; Marianne Dieterich
Journal:  J Neurol       Date:  2018-11-27       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.